Combined analysis of circulating epithelial cells and serum thyroglobulin for distinguishing disease status of the patients with papillary thyroid carcinoma
| Autor: | Jen Der Lin, Yi-An Chen, Hung-Chih Lin, Miaw-Jene Liou, Ching-Ping Tseng, Hsung-Ling Hsu, Jason Chia-Hsun Hsieh |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Pathology medicine.medical_specialty endocrine system diseases medicine.medical_treatment 030209 endocrinology & metabolism Disease thyroglobulin Metastasis Thyroid carcinoma 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Interquartile range thyroid cancer Biomarkers Tumor medicine metastasis Humans Thyroid Neoplasms Thyroid cancer business.industry Epithelial Cells Epithelial cell adhesion molecule Middle Aged Neoplastic Cells Circulating medicine.disease Carcinoma Papillary Oncology chemistry Thyroid Cancer Papillary Hormone receptor circulating epithelial cells 030220 oncology & carcinogenesis papillary thyroid carcinoma cardiovascular system Female Thyroglobulin Clinical Research Paper business |
| Zdroj: | Oncotarget |
| ISSN: | 1949-2553 |
| DOI: | 10.18632/oncotarget.6587 |
| Popis: | Papillary thyroid carcinoma (PTC) accounts for about 80% of the cases in thyroid cancer. Routine surveillance by serum thyroglobulin (Tg) and medical imaging is the current practice to monitor disease progression of the patients. Whether enumeration of circulating epithelial cells (CECs) helps to define disease status of PTC patients was investigated. CECs were enriched from the peripheral blood of the healthy control subjects (G1, n = 17) and the patients at disease-free status (G2, n = 26) or with distant metastasis (G3, n = 22). The number of CECs expressing epithelial cell adhesion molecule (EpCAM) or thyroid-stimulating hormone receptor (TSHR) was determined by immunofluorescence microscopy analyses. The medium number of EpCAM+-CECs was 6 (interquartile range 1-11), 12 (interquartile range 7-16) and 91 (interquartile range 31-206) cells/ml of blood for G1, G2 and G3, respectively. EpCAM+-CEC counts were significantly higher in G3 than in G1 (p < 0.05) and G2 (p < 0.05). The medium number of TSHR+-CECs was 9 (interquartile range 3-13), 16 (interquartile range 10-24) and 100 (interquartile range 31-226) cells/ml of blood for G1, G2 and G3, respectively. The TSHR+-CEC counts also distinguished G3 from G1 (p < 0.05) and G2 (p < 0.05). With an appropriate cut off value of CEC count, the disease status for 97.9% (47/48) of the cases was clearly defined. Notably, the metastatic disease for all patients in G3 (22/22) was revealed by combined analysis of serum Tg and CEC. This study implicates that CEC testing can supplement the current standard methods for monitoring disease status of PTC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|